6505--INTENT TO SOLE SOURCE Radiopharm - Lutathera & Pluvicto - Lebanon VAMC

Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.

• Oct 2, 2026CARDINAL HEALTH 414, LLC$4.6M6505--Lab Supplies | Radiopharm | New 5 year consolidation Lebanon & Pittsburgh - Illuccix | 595 and 646 | EDA: 10/01/2026 VLD | Status: moved to collaboration, once actionable will be assigned to ChrMateriality: <0.01% of $CAH revenue (Low)How big this award is next to the company's revenue over the last 12 months: Low under 1%, Medium 1-5%, High 5% or more. Award amount divided by revenue from the company's SEC filings. For this company the latest 10-K year is used. Here: $4.6M award ÷ $254.2B revenue, fiscal year ending Jun 30, 2026 (SEC 10-K). SEC
• Oct 1, 2026CARDINAL HEALTH 414, LLC$638K6505--Fluorodeoxyglucose (FDG) RadiopharmaceuticalMateriality: <0.01% of $CAH revenue (Low)How big this award is next to the company's revenue over the last 12 months: Low under 1%, Medium 1-5%, High 5% or more. Award amount divided by revenue from the company's SEC filings. For this company the latest 10-K year is used. Here: $638K award ÷ $254.2B revenue, fiscal year ending Jun 30, 2026 (SEC 10-K). SEC
• Sep 2, 2026CARDINAL HEALTH 414, LLC$3.6M6505--Lab Supplies | Radiopharm | 5-Year Indefinite Delivery/Indefinite Quantity (IDIQ) | VA Pittsburgh Healthcare SystemMateriality: <0.01% of $CAH revenue (Low)How big this award is next to the company's revenue over the last 12 months: Low under 1%, Medium 1-5%, High 5% or more. Award amount divided by revenue from the company's SEC filings. For this company the latest 10-K year is used. Here: $3.6M award ÷ $254.2B revenue, fiscal year ending Jun 30, 2026 (SEC 10-K). SEC
• Jul 25, 2026CARDINAL HEALTH 414, LLC$3.6M6505--Lab Supplies | Radiopharm | 5-Year Indefinite Delivery/Indefinite Quantity (IDIQ) | VA Pittsburgh Healthcare SystemMateriality: <0.01% of $CAH revenue (Low)How big this award is next to the company's revenue over the last 12 months: Low under 1%, Medium 1-5%, High 5% or more. Award amount divided by revenue from the company's SEC filings. For this company the latest 10-K year is used. Here: $3.6M award ÷ $254.2B revenue, fiscal year ending Jun 30, 2026 (SEC 10-K). SEC
• Apr 2, 2026CARDINAL HEALTH 414, LLC$2.7M6505--Intent to Sole Source | Xofigo RA-223 | Brand Name Only 5 YR-Indefinite Delivery/Indefinite Quantity (IDIQ) Multiple Stations (646, 642, 595)Materiality: <0.01% of $CAH revenue (Low)How big this award is next to the company's revenue over the last 12 months: Low under 1%, Medium 1-5%, High 5% or more. Award amount divided by revenue from the company's SEC filings. For this company the latest 10-K year is used. Here: $2.7M award ÷ $254.2B revenue, fiscal year ending Jun 30, 2026 (SEC 10-K). SEC
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$249K6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$127K6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$2.0M6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$3.4M6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$1.0M6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.